Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy-Reference-Cited by-同舟云学术

Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy

Published:2019-03 Issue:3 Volume:143 Page:1067-1076
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Shamji Mohamed H.,Kappen Jasper,Abubakar-Waziri Hisham,Zhang Jinjin,Steveling Esther,Watchman Shelley,Kouser Lubna,Eifan Aarif,Switzer Amy,Varricchi Gilda,Marone Gianni,Couto-Francisco Natália C.,Calderon Moises,Durham Stephen R.

Funder

Royal Brompton Hospital NHS Trust research funds, United Kingdom

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference36 articles.

1. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper;Bousquet;J Allergy Clin Immunol,1998

2. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy;Shamji;Allergy,2012

3. Long-term clinical efficacy of grass-pollen immunotherapy;Durham;N Engl J Med,1999

4. Allergen injection immunotherapy for seasonal allergic rhinitis;Calderon;Cochrane Database Syst Rev,2007

5. Pathophysiology of allergic rhinitis;Bousquet;Int Arch Allergy Immunol,1996

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MUW researcher of the month;Wiener klinische Wochenschrift;2024-09

2. Evaluation of the Correlation Between Nasal Secretion ECP-MPO Test Papers and Immune Markers in Subcutaneous Immunotherapy of Dust Mites;Journal of Asthma and Allergy;2024-09

3. Sublingual allergen immunotherapy prevents house dust mite inhalant type 2 immunity through dendritic cell-mediated induction of Foxp3+ regulatory T cells;Mucosal Immunology;2024-08

4. Human T follicular helper cells and their impact on IgE and IgG4 production across allergy, malignancy, and IgG4-related disease;Allergology International;2024-08

5. PREVAX: A Phase I Clinical Trial of an EGF-Based Vaccine in Moderate-to-Severe COPD Patients;Vaccines;2024-07-24